NE10790

• CAT Number: I008020
• CAS Number: 152831-36-2
• PubChem Substance ID: 10014835
• Molecular Formula: C8H10NO6P
• Molecular Weight: 247.143
• Purity: 98%
• Synonyms: NE10790; NE 10790; NE-10790.;2-hydroxy-2-phosphono-3-(pyridin-3-yl)propanoic acid
• Solubility: Soluble in DMSO
• Appearance: White to off-white solid
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• Analysis method: HPLC
• IUPAC Name: 2-hydroxy-2-phosphono-3-pyridin-3-ylpropanoic acid
• InChI: InChI=1S/C8H10NO6P/c10-7(11)8(12,16(13,14)15)4-6-2-1-3-9-5-6/h1-3,5,12H,4H2,(H,10,11)(H2,13,14,15)
• InChIKey: FJVYPXVLXQXDHM-UHFFFAOYSA-N
• SMILES: C1=CC(=CN=C1)CC(C(=O)O)(O)P(=O)(O)O

NE 10790 (CAT: I008020) is a phosphonocarboxylate analogue of the bisphosphonate risedronate and a poor inhibitor of farnesyl pyrophosphate synthase. It exhibits weak antiresorptive activity and has a significantly reduced binding affinity compared to risedronate. Despite its reduced bone affinity, NE 10790 still retains some level of antiresorptive activity. The group of phosphonocarboxylates, including NE 10790, presents an intriguing therapeutic option due to their distinct properties and potential applications. Further research and development in this area may uncover their therapeutic potential in various contexts.

Reference

1. Int J Cancer. 2009 Sep 1;125(5):1177-85. doi: 10.1002/ijc.24436.

Cancer-induced bone loss and associated pain-related behavior is reduced by
risedronate but not its phosphonocarboxylate analog NE-10790.

Hald A(1), Hansen RR, Thomsen MW, Ding M, Croucher PI, Gallagher O, Ebetino FH,
Kassem M, Heegaard AM.

Author information:
(1)Department of Pharmacology and Pharmacotherapy, University of Copenhagen,
Denmark.

Prostate, breast and lung cancers readily develop bone metastases which lead to
fractures, hypercalcemia and pain. Malignant growth in the bones depends on
osteoclast-mediated bone resorption and in this regard bisphosphonate compounds,
which have high-bone affinity and inhibit osteoclast activity, have been found
to alleviate bone cancer symptoms. In this study, the bisphosphonate risedronate
and its phosphonocarboxylate derivative NE-10790 was tested in a murine bone
cancer pain model. Risedronate decreased bone cancer-related bone destruction
and pain-related behavior and decreased the spinal expression of glial
fibrillary acidic protein, whereas NE-10790 had no effect on these parameters.
Furthermore, risedronate but not NE-10790 induced dose-dependent toxicity in
NCTC-2472 cells in vitro. Furthermore, the direct toxic effect of risedronate on
tumor cells observed in vitro opens the possibility that a direct toxic effect
on tumor cells may also be present in vivo and be related to the efficacy of
bisphosphonate compounds. In conclusion, these results suggest that risedronate
treatment may lead to an increased life quality, in patient suffering from bone
cancer, in terms of decreased osteolysis and pain, and merits further study.